New opportunities for skin sensitization testing with GARD®skin OECD TG 442E
Come meet us at booth #36 and join our poster presentations to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development.
Meet also ToxHub, our latest addition to the Group, and benefit from expert Toxicology and Regulatory advice.
Booth #36
Discuss your toxicological risk assessment needs with us!
Posters
Spotlight on Difficult-to-Test, Quantitative Potency, Medical Devices and E&L Assessment
→ Joint poster with Exxon Mobil
P07-02 | Assessing the utility of the Genomic Allergen Rapid Detection (GARD®skin) assay to detect dermal sensitization potential in UVCBs and formulated lubricant products
→ Joint poster with IFF and RIFM
P22-43 | The GARD® skin Dose-Response assay for determination of a point-of-departure (PoD) for Next Generation Risk Assessment (NGRA) of skin sensitizers: A case study using isocyclocitral
→ Joint poster with Duearity
P22-30 | Regulatory approval of medical devices according to MDR using in vitro data from GARD® skin Medical Device for skin sensitization assessment
→ ToxHub poster
LP-38 | Toxicological risk assessment of extractable and leachable compounds: mitigating risks in pharmaceutical applications
New
Tailored Toxicology Services
At our booth, you will also meet our independent consultancy unit Toxhub, specialized in toxicological risk assessment and regulatory strategy consulting, with expertise in pharmaceuticals, chemicals, medical devices and cosmetics.
